ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in B-Cell Non-Hodgkin Lymphoma. According to Globaldata, it is involved in 4 clinical trials, of which 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of ADI-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData


Premium Insights Net Present Value Model: Adicet Bio Inc's ADI-001

Buy the Model

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for ADI-001 is expected to reach an annual total of $35 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ADI-001 Overview

ADI-001 is under development for the treatment of non-Hodgkin’s lymphomas including follicular lymphoma, mantle-cell lymphoma, marginal zone lymphoma, mediastinal lymphoma, diffuse large b cell lymphoma. The therapeutic candidate comprises of allogenic gamma delta T cells expressing chimeric antigen receptors (CARs) directed to CD20. It acts by targeting cells expressing CD20. It is administered via parenteral route. The therapeutic candidate is being developed based on universal immune cell therapy (uICT) platform technology and T cell receptor-like monoclonal antibodies (TCRLs).

It was under development for the treatment of chronic lymphocytic leukemia (CLL), burkitt lymphoma.

Adicet Bio Overview

Adicet Bio, formerly resTORbio, is a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio is headquartered in Boston, Massachusetts, the US.
The company reported revenues of (US Dollars) US$25 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$9.7 million in FY2021. The operating loss of the company was US$72.6 million in FY2022, compared to an operating loss of US$61.4 million in FY2021. The net loss of the company was US$69.8 million in FY2022, compared to a net loss of US$62 million in FY2021.

For a complete picture of ADI-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.